These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 28804955)

  • 1. 3M-052 as an adjuvant for a PLGA microparticle-based Leishmania donovani recombinant protein vaccine.
    Wang Q; Barry MA; Seid CA; Hudspeth EM; McAtee CP; Heffernan MJ
    J Biomed Mater Res B Appl Biomater; 2018 May; 106(4):1587-1594. PubMed ID: 28804955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.
    Aguilar-Be I; da Silva Zardo R; Paraguai de Souza E; Borja-Cabrera GP; Rosado-Vallado M; Mut-Martin M; García-Miss Mdel R; Palatnik de Sousa CB; Dumonteil E
    Infect Immun; 2005 Feb; 73(2):812-9. PubMed ID: 15664920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble
    Margaroni M; Agallou M; Athanasiou E; Kammona O; Kiparissides C; Gaitanaki C; Karagouni E
    Int J Nanomedicine; 2017; 12():6169-6184. PubMed ID: 28883727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The F1F3 Recombinant Chimera of
    Alves-Silva MV; Nico D; de Luca PM; Palatnik de-Sousa CB
    Front Immunol; 2019; 10():724. PubMed ID: 31024556
    [No Abstract]   [Full Text] [Related]  

  • 5. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis.
    Das P; Paik D; Naskar K; Chakraborti T
    Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NH36 and F3 Antigen-Primed Dendritic Cells Show Preserved Migrating Capabilities and CCR7 Expression and F3 Is Effective in Immunotherapy of Visceral Leishmaniasis.
    Nico D; Martins Almeida F; Maria Motta J; Soares Dos Santos Cardoso F; Freire-de-Lima CG; Freire-de-Lima L; de Luca PM; Maria Blanco Martinez A; Morrot A; Palatnik-de-Sousa CB
    Front Immunol; 2018; 9():967. PubMed ID: 29867949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive immunity against Leishmania nucleoside hydrolase maps its c-terminal domain as the target of the CD4+ T cell-driven protective response.
    Nico D; Claser C; Borja-Cabrera GP; Travassos LR; Palatnik M; Soares IS; Rodrigues MM; Palatnik-de-Sousa CB
    PLoS Negl Trop Dis; 2010 Nov; 4(11):e866. PubMed ID: 21085470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani.
    Gamboa-León R; Paraguai de Souza E; Borja-Cabrera GP; Santos FN; Myashiro LM; Pinheiro RO; Dumonteil E; Palatnik-de-Sousa CB
    Vaccine; 2006 May; 24(22):4863-73. PubMed ID: 16635538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
    Ravindran R; Maji M; Ali N
    Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleoside Hydrolase NH 36: A Vital Enzyme for the
    Palatnik-de-Sousa CB
    Front Immunol; 2019; 10():813. PubMed ID: 31040850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection.
    Daifalla NS; Bayih AG; Gedamu L
    Exp Parasitol; 2012 Jul; 131(3):317-24. PubMed ID: 22580023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic properties.
    Hudspeth EM; Wang Q; Seid CA; Hammond M; Wei J; Liu Z; Zhan B; Pollet J; Heffernan MJ; McAtee CP; Engler DA; Matsunami RK; Strych U; Asojo OA; Hotez PJ; Bottazzi ME
    Hum Vaccin Immunother; 2016 Jul; 12(7):1707-20. PubMed ID: 26839079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
    Bhowmick S; Ravindran R; Ali N
    Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression, purification, immunogenicity and protective efficacy of a recombinant nucleoside hydrolase from Leishmania donovani, a vaccine candidate for preventing cutaneous leishmaniasis.
    McAtee CP; Seid CA; Hammond M; Hudspeth E; Keegan BP; Liu Z; Wei J; Zhan B; Arjona-Sabido R; Cruz-Chan V; Dumonteil E; Hotez PJ; Bottazzi ME
    Protein Expr Purif; 2017 Feb; 130():129-136. PubMed ID: 27773761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction and analysis of promiscuous T cell-epitopes derived from the vaccine candidate antigens of Leishmania donovani binding to MHC class-II alleles using in silico approach.
    Kashyap M; Jaiswal V; Farooq U
    Infect Genet Evol; 2017 Sep; 53():107-115. PubMed ID: 28549876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular, biochemical characterization and assessment of immunogenic potential of cofactor-independent phosphoglycerate mutase against Leishmania donovani: a step towards exploring novel vaccine candidate.
    Tandon R; Chandra S; Baharia RK; Misra P; Das S; Rawat K; Siddiqi MI; Sundar S; Dube A
    Parasitology; 2018 Apr; 145(4):508-526. PubMed ID: 28691653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis.
    Stäger S; Smith DF; Kaye PM
    J Immunol; 2000 Dec; 165(12):7064-71. PubMed ID: 11120835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis.
    Thakur A; Kaur H; Kaur S
    Parasitol Int; 2015 Feb; 64(1):70-8. PubMed ID: 25316605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R; Kaur S
    Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Leishmania hypothetical protein-containing liposome-based formulation is highly immunogenic and induces protection against visceral leishmaniasis.
    Ribeiro PAF; Dias DS; Novais MVM; Lage DP; Tavares GSV; Mendonça DVC; Oliveira JS; Chávez-Fumagalli MA; Roatt BM; Duarte MC; Menezes-Souza D; Ludolf F; Tavares CAP; Oliveira MC; Coelho EAF
    Cytokine; 2018 Nov; 111():131-139. PubMed ID: 30142534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.